The hydroxamate based HDAC inhibitor WMJ-J-09 induces colorectal cancer cell death by targeting tubulin and downregulating survivin
Abstract Aberrant expression of histone deacetylases (HDACs) is associated with cancer drug resistance and tumor progression. While considerable studies and effort have been devoted to developing novel HDAC inhibitors in cancer therapy, hydroxamate-based HDAC inhibitors have gained growing interest...
Saved in:
| Main Authors: | Yu-Han Huang, Yu-Min Huang, Wei-Jan Huang, Meng-Chieh Yu, Chin-Hui Chuang, Ya-Fen Hsu, Hsiu-Chen Chen, Liang-Chieh Chen, Shiu-Wen Huang, Ming-Jen Hsu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-06-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-04714-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
HDAC1 and HDAC2 Are Involved in Influenza A Virus-Induced Nuclear Translocation of Ectopically Expressed STAT3-GFP
by: Jessica Leong, et al.
Published: (2024-12-01) -
Development of novel benzamide class I selective lysine deacetylase inhibitors as potent anticancer agents
by: Jason H. Gill, et al.
Published: (2025-12-01) -
Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors
by: Dandan Yuan, et al.
Published: (2025-12-01) -
Histone Deacetylase 6 (HDAC6) in Ciliopathies: Emerging Insights and Therapeutic Implications
by: Zhiyi Wang, et al.
Published: (2025-06-01) -
Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors
by: Julia Krushkal, et al.
Published: (2024-12-01)